NextGen - CHOP
下一代 - CHOP
基本信息
- 批准号:10845769
- 负责人:
- 金额:$ 53.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-24 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAgreementAntigensAreaAutologousB-Cell Acute Lymphoblastic LeukemiaB-LymphocytesBackBiologicalBrain NeoplasmsCAR T cell therapyCancer PatientCancer RelapseCell TherapyCell physiologyCharacteristicsChildChildhoodChildhood Cancer TreatmentChildhood LeukemiaChildhood Solid NeoplasmClinicClinicalClinical ResearchClinical TrialsCommunitiesComplexCoupledCouplingCustomCytometryDataData CollectionDatabasesDevelopmentDiseaseEngineeringGenerationsGenetic EngineeringHeartHematologic NeoplasmsImmuneImmune EvasionImmunosuppressionImmunotherapyKnowledgeLearningLifeMalignant Childhood NeoplasmMalignant NeoplasmsMalignant lymphoid neoplasmMass Spectrum AnalysisMethodsModelingMutationNeuroblastomaOperative Surgical ProceduresPatientsPediatric NeoplasmPediatric OncologyPlasma CellsPre-Clinical ModelPrimary NeoplasmProgram DevelopmentProtein EngineeringRadiationRefractoryRelapseResearch DesignResearch PersonnelResistanceRouteSolidSolid NeoplasmStructureSurface AntigensSurvival RateSurvivorsSystemT cell therapyT-LymphocyteTechnologyTestingTextTherapeuticToxic effectTranslatingVisionWorkXenograft procedurebench to bedsidecancer cellcancer typecellular engineeringchemotherapychildhood sarcomachimeric antigen receptorchimeric antigen receptor T cellsclinical developmentclinical translationcomorbiditydata complexitydata integrationdata sharingdesigndiffuse midline gliomaengineered T cellshigh riskimmune checkpoint blockadeimprovedin vivoin vivo Modelmanufactureneoplastic cellnext generationnovelphase I trialpre-clinicalpreclinical developmentprogramsreceptorresponsesharing platformsmall moleculestandard of caretumortumor heterogeneitytumor microenvironment
项目摘要
Next Generation T cell therapies for childhood cancers [NexTGen]
Current treatments fail to cure many children with solid cancers. Recent advances in adult cancers such as checkpoint blockade and targeted small molecules have made little impact in childhood disease. Engineered T-cell therapies can achieve durable responses in refractory lymphoid cancers without long-term toxicity. These are precisely the characteristics required for new treatments for pediatric solid cancers. In contrast to hematologic malignancies, solid cancers are challenging due to a lack of targets, tumor heterogeneity, and hostile tumor microenvironment (TME). We posit that through advanced cellular engineering we can overcome these challenges. Our vision is that engineered T-cell therapy for childhood solid cancers will become routine within a decade. Our central hypothesis is that coupling of advanced cellular engineering along with progressive clinical development is the fastest route to developing effective T-cell therapies for pediatric solid tumors. In NexTGen, we combine detailed studies of primary tumors to discover new targets and understand how the TME subverts T- cell function. This, along with a closely coupled clinical development program will guide the progressive engineering of T-cells to result in transformative therapies. NexTGen is composed of 6 inter-connected work-packages (WPs) with work initially focused on pediatric sarcomas and brain tumors. AIMS: WP1: To identify suitable targets for engineered T-cells. WP2: To understand the TME in pediatric solid cancers. WP3: To develop receptors and other engineering components which target tumor cells and resist or modulate the TME. WP4: To evaluate the function of engineered T-cells developed in WP3. WP5: To translate approaches from WP4 and test them in clinical studies designed for maximal impact. Cancer Grand Challenges - Full Application - 2021 WP6: To promote data sharing across all WPs. METHODS: Target discovery (WP1) and TME studies (WP2) will utilize mass spectroscopy and chip cytometry respectively. Component engineering (WP3) will use protein engineering methods. To model engineered cell function, WP4 will mostly use intact tumor models such as immune PDXs. In WP5, clinical product generation will involve autologous closed system semi-automated manufacturing. WP6 uses standard and custom databases and data sharing platforms. USE OF RESULTS: Tumor target and TME data from WP1 and 2 will be uploaded to databases developed by WP6 for widespread distribution. Engineering components from WP3 and functional data from WP4 will be available for incorporation into therapeutic T-cell strategies by the entire community. Clinical study data from WP5 should lead to registration studies, improving cure rates and mitigation of long-term toxicity to realize our Vision.
儿童癌症的下一代T细胞疗法[NextGen]
目前的治疗方法无法治愈许多患有实体癌症的儿童。成人癌症的最新进展,如检查点封锁和靶向小分子,对儿童疾病几乎没有影响。基因工程T细胞疗法可以在难治性淋巴癌中取得持久的反应,而不会产生长期毒性。这些正是儿童实体癌新疗法所需要的特征。与血液系统恶性肿瘤相比,实体癌由于缺乏靶点、肿瘤的异质性和恶性的肿瘤微环境(TME)而具有挑战性。我们假定,通过先进的细胞工程,我们可以克服这些挑战。我们的愿景是,工程T细胞疗法将在十年内成为儿童实体癌症的常规疗法。我们的中心假设是,结合先进的细胞工程和不断进步的临床发展,是开发有效的儿童实体瘤T细胞疗法的最快途径。在NextGen中,我们结合了对原发肿瘤的详细研究,以发现新的靶点,并了解TME如何颠覆T细胞功能。这与紧密结合的临床开发计划将指导T细胞的进步工程,以产生变革性的治疗方法。NextGen由6个相互关联的工作包(WPS)组成,最初的工作重点是儿童肉瘤和脑瘤。目的:WP1:为工程化T细胞寻找合适的靶点。WP2:了解儿童实体肿瘤的TME。WP3:开发针对肿瘤细胞的受体和其他工程组件,并抵抗或调节TME。WP4:评价WP3培养的工程化T细胞的功能。WP5:翻译来自WP4的方法,并在为最大影响而设计的临床研究中测试它们。癌症大挑战-全面应用-2021年WP6:促进所有WP之间的数据共享。方法:靶点发现(WP1)和TME研究(WP2)将分别利用质谱学和芯片细胞术。组份工程(WP3)将使用蛋白质工程方法。为了模拟工程细胞的功能,WP4将主要使用完整的肿瘤模型,如免疫PDX。在WP5中,临床产品的产生将涉及自体封闭系统的半自动制造。WP6使用标准和定制的数据库和数据共享平台。结果的使用:来自WP1和2的肿瘤靶点和TME数据将被上传到WP6开发的数据库以供广泛分发。来自WP3的工程组件和来自WP4的功能数据将被整个社区纳入治疗T细胞策略。来自WP5的临床研究数据应该导致注册研究,提高治愈率和减轻长期毒性,以实现我们的愿景。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN M MARIS其他文献
JOHN M MARIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN M MARIS', 18)}}的其他基金
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
儿童癌症最佳免疫治疗策略的发现和开发
- 批准号:
10217467 - 财政年份:2018
- 资助金额:
$ 53.77万 - 项目类别:
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
儿童癌症最佳免疫治疗策略的发现和开发
- 批准号:
10578307 - 财政年份:2018
- 资助金额:
$ 53.77万 - 项目类别:
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
儿童癌症最佳免疫治疗策略的发现和开发
- 批准号:
10578310 - 财政年份:2018
- 资助金额:
$ 53.77万 - 项目类别:
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
发现和利用神经母细胞瘤治疗耐药的机制
- 批准号:
9359221 - 财政年份:2017
- 资助金额:
$ 53.77万 - 项目类别:
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
发现和利用神经母细胞瘤治疗耐药的机制
- 批准号:
10265471 - 财政年份:2017
- 资助金额:
$ 53.77万 - 项目类别:
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes
发现神经母细胞瘤肿瘤发生机制以改善患者预后
- 批准号:
9390172 - 财政年份:2017
- 资助金额:
$ 53.77万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 53.77万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 53.77万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 53.77万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 53.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 53.77万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 53.77万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 53.77万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 53.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 53.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 53.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)